Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity

Journal of Infectious Diseases

Volumn 216, Issue , 2017, Pages S906-S911

  Priyamvada, Lalita ^a   Suthar, Mehul S ^a   Ahmed, Rafi ^a   Wrammert, Jens ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibody; antibody dependent enhancement; dengue virus; flavivirus; humoral immunity; Zika virus

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C10; MONOCLONAL ANTIBODY Z23; MONOCLONAL ANTIBODY ZIKV 117; MONOCLONAL ANTIBODY ZKA64; MONOCLONAL ANTIBODY ZV 54; MONOCLONAL ANTIBODY ZV 67; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; ZIKA VIRUS VACCINE; VIRUS VACCINE;

ANTIBODY DEPENDENT ENHANCEMENT; B LYMPHOCYTE; CROSS REACTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; FLAVIVIRUS; HUMAN; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; NONHUMAN; PLASMABLAST; PRIORITY JOURNAL; REVIEW; VIRUS IMMUNITY; ZIKA FEVER; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY; ZIKA VIRUS;

ANTIBODY-DEPENDENT ENHANCEMENT; B-LYMPHOCYTES; CROSS REACTIONS; FLAVIVIRUS; HUMANS; IMMUNITY, HUMORAL; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85040251689     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix513     Document Type: Review

References (63)

1. Miner JJ, Diamond MS. Zika virus pathogenesis and tissue tropism. Cell Host Microbe 2017; 21:134-42.
2. Morrison TE, Diamond MS. Animal models of Zika virus infection, pathogenesis, and immunity. J Virol 2017; 91: e00009-17.
3. Cao B, Diamond MS, Mysorekar IU. Maternal-fetal transmission of Zika virus: routes and signals for infection. J Interferon Cytokine Res 2017; 37:287-94.
4. Andrade DV, Harris E. Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure. Virus Res 2017. In press. doi: 10.1016/j.virusres.2017.06.019.
5. Fernandez E, Diamond MS. Vaccination strategies against Zika virus. Curr Opin Virol 2017; 23:59-67.
6. McArthur MA. Zika virus: recent advances towards the development of vaccines and therapeutics. Viruses 2017; 9: 143.
7. Stettler K, Beltramello M, Espinosa DA, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 2016; 353:823-6.
8. Rogers TF, Goodwin EC, Briney B, et al. Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. Sci Immunol 2017; 2: eaan6809.
9. Yu L, Wang R, Gao F, et al. Delineating antibody recognition against Zika virus during natural infection. JCI Insight 2017; 2: e93042.
10. Lai L, Rouphael N, Xu Y, et al. Innate, T and B cell responses in acute human Zika patients. Clin Infect Dis 2017. doi:10.1093/cid/cix732.
11. Robbiani DF, Bozzacco L, Keeffe JR, et al. Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell 2017; 169:597-609.e11.
12. Dejnirattisai W, Supasa P, Wongwiwat W, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat Immunol 2016; 17:1102-8.
13. Zhao H, Fernandez E, Dowd KA, et al. Structural basis of Zika virus-specific antibody protection. Cell 2016; 166:1016-27.
14. Swanstrom JA, Plante JA, Plante KS, et al. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. MBio 2016; 7: e01123-16.
15. Wang Q, Yang H, Liu X, et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci Transl Med 2016; 8:369ra179.
16. Priyamvada L, Quicke KM, Hudson WH, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A 2016; 113:7852-7.
17. Durbin A, Wilder-Smith A. An update on Zika vaccine developments. Expert Rev Vaccines 2017; 16:781-7.
18. Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 2008; 14:1232-9.
19. Waggoner JJ, Pinsky BA. Zika Virus: Diagnostics for an Emerging Pandemic Threat. J Clin Microbiol 2016; 54:860-7.
20. Priyamvada L, Quicke KM, Hudson WH, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A 2016; 113:7852-7.
21. Collins MH, McGowan E, Jadi R, et al. Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection. Emerg Infect Dis 2017; 23:773-81.
22. Magnani DM, Silveira CGT, Rosen BC, et al. A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus. PLoS Negl Trop Dis 2017; 11:e0005655.
23. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453:667-71.
24. Priyamvada L, Cho A, Onlamoon N, et al. B cell responses during secondary dengue virus infection are dominated by highly cross-reactive, memory-derived plasmablasts. J Virol 2016; 90:5574-85.
25. Liao HX, Chen X, Munshaw S, et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 2011; 208:2237-49.
26. Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208:181-93.
27. Sapparapu G, Fernandez E, Kose N, et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 2016; 540:443-7.
28. Beltramello M, Williams KL, Simmons CP, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010; 8:271-83.
29. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 2012; 429:12-20.
30. Dejnirattisai W, Wongwiwat W, Supasa S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 2015; 16:170-7.
31. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 2016; 536:48-53.
32. Hasan SS, Miller A, Sapparapu G, et al. A human antibody against Zika virus crosslinks the E protein to prevent infection. Nat Commun 2017; 8:14722.
33. Stiasny K, Kiermayr S, Holzmann H, Heinz FX. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 2006; 80:9557-68.
34. Deng YQ, Dai JX, Ji GH, et al. A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One 2011; 6:e16059.
35. Dai L, Song J, Lu X, et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 2016; 19:696-704.
36. Balmaseda A, Stettler K, Medialdea-Carrera R, et al. Antibody-based assay discriminates Zika virus infection from other flaviviruses. Proc Natl Acad Sci U S A 2017; 114:8384-9.
37. Nigro G, Adler SP, La Torre R, Best AM; Congenital Cytomegalovirus Collaborating Group. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005; 353:1350-62.
38. Revello MG, Lazzarotto T, Guerra B, et al.; CHIP Study Group. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 2014; 370:1316-26.
39. Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994; 343:1548-51.
40. Koren G, Money D, Boucher M, et al. Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women. J Clin Pharmacol 2002; 42:267-74.
41. Negishi H, Yamada H, Hirayama E, et al. Intraperitoneal administration of cytomegalovirus hyperimmunoglobulin to the cytomegalovirus-infected fetus. J Perinatol 1998; 18:466-9.
42. Fischer DB, Halstead SB. Observations related to pathogenesis of dengue hemorrhagic fever. V. Examination of agspecific sequential infection rates using a mathematical model. Yale J Biol Med 1970; 42:329-49.
43. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9.
44. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 60:421-67.
45. Peiris JS, Porterfield JS. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. Nature 1979; 282:509-11.
46. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977; 265:739-41.
47. Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328:745-8.
48. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE Jr. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 2012; 86:2665-75.
49. Priyamvada L, Cho A, Onlamoon N, et al. B cell responses during secondary dengue virus infection are dominated by highly cross-reactive, memory-derived plasmablasts. J Virol 2016; 90:5574-85.
50. Balsitis SJ, Williams KL, Lachica R, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 2010; 6:e1000790.
51. Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 2010; 7:128-39.
52. Martinez Gomez JM, Ong LC, Lam JH, et al. Maternal antibody-mediated disease enhancement in Type I interferon-deficient mice leads to lethal disease associated with liver damage. PLoS Negl Trop Dis 2016; 10:e0004536.
53. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 2007; 104:9422-7.
54. Simmons CP, Chau TN, Thuy TT, et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 2007; 196:416-24.
55. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988; 38:411-9.
56. Chau TN, Hieu NT, Anders KL, et al. Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis 2009; 200:1893-900.
57. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al.; CYD-TDV Dengue Vaccine Working Group. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015; 373:1195-206.
58. Villar L, Dayan GH, Arredondo-Garcia JL, et al.; CYD15 Study Group. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372:113-23.
59. Pantoja P, Perez-Guzman EX, Rodriguez IV, et al. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat Commun 2017; 8:15674.
60. Fagbami AH, Halstead SB, Marchette NJ, Larsen K. Cross-infection enhancement among African flaviviruses by immune mouse ascitic fluids. Cytobios 1987; 49:49-55.
61. Dowd KA, DeMaso CR, Pelc RS, et al. Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell Rep 2016; 16:1485-91.
62. Bardina SV, Bunduc P, Tripathi S, et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 2017; 356:175-80.
63. McCracken MK, Gromowski GD, Friberg HL, et al. Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. PLoS Pathog 2017; 13:e1006487.